[Cardiocirculatory effects of a new sympathomimetic, amezinium methyl sulfate. Results of human pharmacological studies].
Changes in haemodynamic, inotropic state, and myocardial oxygen consumption were investigated in a total of eight patients with coronary artery disease after intravenous injection of 0.07 mg/kg amezinium methyl sulfate (LU 1631, Supratonin). It was demonstrated, that the principal effects of amezinium are consistent with those of a sympathomimetic agent which stimulates vascular alpha- and beta 1-adrenoreceptors. Amezinium (0.07 mg/kg) increased cardiac index, mean arterial pressure and total systemic resistance and dp/dtmax, while there were only minor changes in stroke index, mean pulmonary pressure and total pulmonary vascular resistance. In accordance with the changes in haemodynamics there was a 21.5% increase in myocardial oxygen consumption. But there were no signs of imbalance between oxygen supply and oxygen demand.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D011724:Pyridazines / Q000494:pharmacology*; D012039:Regional Blood Flow / Q000187:drug effects; D013566:Sympathomimetics / Q000494:pharmacology*; D013997:Time Factors
D011724:Pyridazines; D013566:Sympathomimetics; C027784:amezinium
Kardiozirkulatorische Effekte des neuen Sympathomimetikums Ameziniummetilsulfat. Ergebnisse humanpharmakologischer Studien.